Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) - Trial NCT04809623
Access comprehensive clinical trial information for NCT04809623 through Pure Global AI's free database. This Phase 1 trial is sponsored by Gilead Sciences and is currently Suspended. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gilead Sciences
Timeline & Enrollment
Phase 1
Sep 01, 2021
Jan 01, 2023
Primary Outcome
Percentage of Participants Experiencing Adverse Events,Percentage of Participants Experiencing Laboratory Abnormalities
Summary
The primary objective of this study is to evaluate the safety and tolerability of GS-5718 in
 participants with Cutaneous Lupus Erythematosus (CLE) with or without Systemic Lupus
 Erythematosus (SLE).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04809623
Non-Device Trial